Validation of three coding algorithms to identify patients with end-stage liver disease in an administrative database

被引:126
|
作者
Goldberg, D. [1 ,2 ]
Lewis, J. D. [1 ,2 ,3 ]
Halpern, S. D. [2 ,3 ,4 ]
Weiner, Mark [2 ,3 ,5 ]
Lo Re, Vincent, III [2 ,6 ]
机构
[1] Univ Penn, Div Gastroenterol, Dept Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Clin Ctr Biostat & Epidemiol, Philadelphia, PA 19104 USA
[3] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA
[4] Univ Penn, Div Pulm Allergy & Crit Care, Dept Med, Philadelphia, PA 19104 USA
[5] Univ Penn, Div Gen Internal Med, Dept Med, Philadelphia, PA 19104 USA
[6] Univ Penn, Div Infect Dis, Dept Med, Philadelphia, PA 19104 USA
关键词
validation; hepatic decompensation; cirrhosis; ICD-9-CM code; end-stage liver disease; pharmacoepidemiology; UNITED-STATES; HEPATITIS; CIRRHOSIS; VALIDITY; BURDEN;
D O I
10.1002/pds.3290
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose Use of administrative or population-based databases for post-marketing pharmacoepidemiology research in patients with end-stage liver disease (ESLD) has been limited by the difficulty of accurately identifying such patients. Algorithms to identify patients with ESLD using ICD-9-CM codes have not been developed outside of the Veterans Affairs healthcare setting. Methods We queried electronic medical records at two tertiary care hospitals to identify patients with ICD-9-CM codes indicative of ESLD. Coding algorithms were developed to identify patients with confirmed ESLD, and these were tested to determine their positive predictive value (PPV). Results The presence of one inpatient or outpatient ICD-9-CM code for: (i) cirrhosis; (ii) chronic liver disease, and (iii) a hepatic decompensation event yielded a PPV of 85.2% (167/196; 95% CI: 79.4%89.9%). The PPV increased to 89.3% (150/168; 95% CI: 83.6%93.5%) when the algorithm required two or more ICD-9-CM codes for a hepatic decompensation. However, an algorithm requiring only one ICD-9-CM code for (i) cirrhosis and (ii) a hepatic decompensation event, in the absence of a chronic liver disease code, yielded a PPV of 85.7% (30/35; 95% CI: 69.7%-95.2%). Conclusions A coding algorithm that includes at least one ICD-9-CM code for cirrhosis plus one ICD-9-CM code for a hepatic decompensation event has a high PPV for identifying patients with ESLD. The inclusion of at least two codes indicative of a hepatic decompensation event increased the PPV. This algorithm can be used in future epidemiologic studies to examine the outcomes of a variety of long-term medical therapies in patients with ESLD. Copyright (c) 2012 John Wiley & Sons, Ltd.
引用
收藏
页码:765 / 769
页数:5
相关论文
共 50 条
  • [1] Validation of a coding algorithm to identify patients with hepatocellular carcinoma in an administrative database
    Goldberg, David S.
    Lewis, James D.
    Halpern, Scott D.
    Weiner, Mark G.
    Lo Re, Vincent, III
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 (01) : 103 - 107
  • [2] Mortality in patients with end-stage liver disease above model for end-stage liver disease 3.0 of 40
    Tarlow, Branden D.
    Kim, W. Ray
    Mannalithara, Ajitha
    Kwo, Paul Y.
    Bonham, C. Andrew
    Kwong, Allison
    [J]. HEPATOLOGY, 2023, 77 (03) : 851 - 861
  • [3] Prehabilitation for Patients With End-Stage Liver Disease
    Derck, Jordan
    Klemptner, Emilie
    Mazurek, Alyssa
    Fakhoury, Joseph
    Sonnenday, Christopher
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15 : 99 - 99
  • [4] Infections in patients with end-stage liver disease
    Cheruvattath, Rekha
    Balan, Vijayan
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 2007, 41 (04) : 403 - 411
  • [5] Heart disease in patients with end-stage liver disease
    Colunga Blanco, S.
    Corros Vicente, C.
    Garcia Campos, A.
    Velasco Alonso, E.
    Diaz Pelaez, E.
    Lopez Iglesias, F.
    Martin Fernandez, M.
    De La Hera Galarza, J. M.
    Lambert Rodriguez, J. L.
    Moris De La Tassa, C.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 : 315 - 315
  • [6] Metabolomics Studies Identify Novel Prognostic Indicators in Patients With End-Stage Liver Disease
    Ascha, Mona
    Ascha, Mustafa
    Dweik, Raed A.
    Zein, Nizar N.
    Brown, J. Mark
    Marshall, Stephanie
    Hazen, Stanley L.
    Wang, Zeneng
    Grove, David
    Hanouneh, Ibrahim A.
    [J]. GASTROENTEROLOGY, 2015, 148 (04) : S975 - S975
  • [7] Mayo end-stage liver disease (MELD) score: Causes of variability in patients with end-stage liver disease (ESLD)
    Yousfi, MM
    Douglas, DD
    Malinchoc, M
    Mulligan, DC
    Rakela, J
    Moss, AA
    Harrison, ME
    Balan, V
    [J]. GASTROENTEROLOGY, 2001, 120 (05) : A371 - A371
  • [8] Cardiovascular dysfunction in patients with end-stage liver disease
    Mandell, Merceds Susan
    Tsou, Mei-Yung
    [J]. JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2008, 71 (07) : 331 - 335
  • [9] The coagulation system in patients with end-stage liver disease
    Valla, Dominique-C.
    Rautou, Pierre-E.
    [J]. LIVER INTERNATIONAL, 2015, 35 : 139 - 144
  • [10] Palliative Care for Patients with End-Stage Liver Disease
    Larson A.M.
    [J]. Current Gastroenterology Reports, 2015, 17 (5)